Agarikonthe reference layer for psychedelic medicine
Blog Methodology Open the index
Trials · built Nov 18, 2026

265 ketamine and psychedelic trials are recruiting, out of 1,604 registered

The research base is larger than the headlines suggest and more lopsided. We track 1,604 registered studies across 4,528 sites, and depression accounts for more recruiting work than PTSD, addiction and OCD combined. This is the map of what's actually being tested, and where you could join it.

1,604registered studies
265recruiting
581recruiting sites worldwide
4,528trial sites indexed

What's being studied

Depression
100
Other
46
Chronic pain & headache
41
Addiction & substance use
34
PTSD & trauma
32
Healthy volunteers
19
Neurology & cognition
17

Depression dominates, which reflects where the money went after the 2018 breakthrough-therapy designations rather than where the need is widest. Chronic pain and headache are the quiet surprise in this data: 41 recruiting studies, a category most coverage ignores entirely. Cancer-related distress, the work that arguably produced psychedelic medicine's most striking early results, is down to 11 recruiting studies, and end-of-life and palliative care to 1.

Counts use the conditions each sponsor filed with the registry, so a study can sit in more than one group. These are the same groups the live index filters on.

How far along the field is

Phase 2
366
Phase 1
287
Phase 4
212
Phase 3
135
Early phase 1
88
Phase 1/Phase 2
78

Phase 4 studies outnumber phase 3, which looks odd until you remember that ketamine and esketamine are already approved drugs and much of that phase 4 volume is post-approval work on them. Strip those out and the genuinely novel compounds are still clustered in phase 1 and 2. A psilocybin approval is not close in the way press coverage implies.

1,604studies
581recruiting
Nov 18build
The live index
581 recruiting sites on the live map Open Research & Trials, toggle Recruiting, zoom to your region. Every site links to its ClinicalTrials.gov registration. Explore the map →

Who's running them

The most active recruiting sponsors in the current data: Johns Hopkins University, Yale University, University Hospital, Basel, Switzerland, National Institute of Mental Health (NIMH). University hospitals and a handful of well-capitalised sponsors carry most of the load, which is worth knowing when you evaluate a study: an academic center running its third psilocybin protocol is a different proposition from a first-time site.

Joining one

Trials are medically supervised, slow, and you might get placebo. If that trade works for you, the recruiting sites list is sorted by country and state, and the enrollment walkthrough covers screening, what to ask, and the mistakes that get people excluded.